Serious adverse events · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes serious adverse events compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Quality of life · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes quality of life compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Pain · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Return to normal activities (days) · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Patient readmissions · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes number of hospital readmissions compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Failed discharge · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes failed discharge compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Intervention not reported
Peg interferon vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes peg interferon vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Peg interferon plus ribavirin vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes peg interferon plus ribavirin vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Ribavirin plus peg interferon vs.peg interferon · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes ribavirin plus peg interferon vs.peg interferon (very low certainty).
1 finding from 1 review
Intervention not reported
Interferon vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes interferon vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Interferon plus ribavirin vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes interferon plus ribavirin vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Ribavirin vs.interferon · Participants with recurrent liver graft infection with hepatitis C virus.
1 finding from 1 review
Intervention not reported
Ribavirin vs.placebo · Participants with recurrent liver graft infection with hepatitis C virus.
1 finding from 1 review
Intervention not reported
Retransplantation after start of therapy ‐ ribavirin vs.placebo · Participants with recurrent liver graft infection with hepatitis C virus.
1 finding from 1 review
Intervention not reported
Retransplantation after start of therapy ‐ interferon vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes retransplantation after start of therapy ‐ interferon vs.control (very low certainty).
1 finding from 1 review
Serious adverse events · patients with laparoscopic cholecystectomy.
It is very uncertain whether miniport laparoscopic cholecystectomy changes serious adverse events compared with standard port laparoscopic cholecystectomy (very low certainty).
1 finding from 1 review
Quality of life · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Conversion to open cholecystectomy · patients with laparoscopic cholecystectomy.
It is very uncertain whether miniport laparoscopic cholecystectomy changes conversion to open cholecystectomy compared with standard port laparoscopic cholecystectomy (very low certainty).
1 finding from 1 review
Operating time · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Length of hospital stay · patients with laparoscopic cholecystectomy.
1 finding from 1 review